NKGN · As filed with the SEC
NKGen Biotech income statement, by fiscal year
The statement as NKGen Biotech presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
CONSOLIDATED STATEMENTS OF OPERATIONS · USD thousands, except per-share amounts
| USD thousands, except per-share amounts | FY2024 Year ended Dec 31, 2024 | FY2023 Year ended Dec 31, 2023 | FY2022 Year ended Dec 31, 2022 | FY2021 Year ended Dec 31, 2021 |
|---|---|---|---|---|
| Costs and expenses: | ||||
| Cost of revenues | — | 0 | — | — |
| Research and development expenses | 10,656 | 15,668 | — | — |
| General and administrative | 16,310 | 14,078 | 2,390.89 | — |
| General and administrative expenses - related party | — | — | 180,000 | — |
| Franchise tax expenses | — | — | 169,141 | — |
| Total expenses | 26,966 | 29,746 | — | — |
| Loss from operations | (26,966) | (29,746) | (2,740.03) | — |
| Other income (expense): | ||||
| Interest expense (including related party amounts of $431 and $2,271 for the year ended December 31, 2023 and 2022, respectively) | — | (745) | — | — |
| Change in fair value of convertible promissory notes and convertible promissory notes due to related parties (including related party amounts of $12 and $4 for the years ended December 31, 2023 and 2022, respectively) | — | (1,043) | — | — |
| Loss on issuance of forward purchase contract | — | (24,475) | — | — |
| Loss on amendment of forward purchase contract | — | (442) | — | — |
| Change in fair value of forward purchase derivative liability | — | (9,784) | — | — |
| Change in fair value of derivative warrant liabilities | — | (13,503) | 5,146.47 | — |
| Gain from extinguishment of deferred underwriting commissions allocated to derivative warrant liability | — | — | 179,595 | — |
| Income from investments held in Trust Account | — | — | 2,400,690 | — |
| Transaction costs expensed | — | (3,329) | — | — |
| Interest expense (including related party amounts of $(1,620) and $(431) for the years ended December 31, 2024 and 2023, respectively) | (2,724) | — | — | — |
| Change in fair value of financial instruments (including related party amounts of $1,825 and $(12) for the years ended December 31, 2024 and 2023, respectively) | 16,072 | — | — | — |
| Loss on issuance of financial instruments (including related party amounts of $(639) and zero for the years ended December 31, 2024 and 2023, respectively) | (25,959) | — | — | — |
| Loss on amendments to financial instruments, net | (4,650) | — | — | — |
| Transaction costs expensed | 0 | — | — | — |
| Other, net | (6) | 120 | — | — |
| Net loss before provision for income taxes | — | (82,947) | 4,986.73 | — |
| Total other income (expense) | (17,267) | — | 7,726.76 | — |
| Net loss before provision for income taxes | (44,233) | — | — | — |
| Provision for income taxes | (53) | (7) | (438.37) | — |
| Net loss | (44,286) | (82,954) | 4,548.35 | — |
| Comprehensive loss | — | (82,954) | — | — |
| Weighted-average common shares outstanding, basic (in shares) | 28,830,356 | 15,426,908 | 21,451,875 | — |
| Weighted-average common shares outstanding, diluted (in shares) | 28,830,356 | 15,426,908 | 21,451,875 | — |
| Net loss per share, basic (in usd per share) | (1.54) | (5.38) | 0.21 | — |
| Net loss per share, diluted (in usd per share) | (1.54) | (5.38) | 0.39 | — |
| Revenues | — | 0 | — | — |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.
Data on this page was fetched . The filing on SEC.gov is the record.